Other Events ·
ORIC Pharmaceuticals, Inc. held its annual meeting of stockholders on June 18, 2026, where shareholders approved the…
ORICOric Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. held its annual meeting of stockholders on June 18, 2026, where shareholders approved the amendment and restatement of the 2020 Equity Incentive Plan. Key changes to the plan include reducing the annual evergreen increase from 5% to 4% of outstanding common stock, removing a fixed 2,656,500 share annual limit, and setting a maximum cap of 10,000,000 shares for incentive stock options. Additionally, the company elected Jacob M. Chacko and Mardi C. Dier as Class III directors, ratified KPMG LLP as the independent auditor, and approved annual advisory votes on executive compensation. The company is a biopharmaceutical firm focused on developing oncology therapies.